SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
Rhea-AI Summary
SI-BONE (SIBN) reported strong Q4 2024 financial results with worldwide revenue reaching $49.0 million, up 26% year-over-year. U.S. revenue grew 28% to $46.9 million. The company achieved positive adjusted EBITDA of $1.9 million in Q4, a 139% improvement.
For full-year 2024, worldwide revenue increased 20% to $167.2 million, with U.S. revenue up 21% to $158.4 million. The company reduced its net loss by 29% to $30.9 million. Gross margin remained stable at 79%.
Looking ahead, SI-BONE provided 2025 guidance, projecting worldwide revenue between $193.5-$195.5 million, representing 16-17% growth. The company expects to achieve positive adjusted EBITDA for both second half and full year 2025, with gross margins forecasted at 77-78%.
Positive
- Q4 2024 worldwide revenue grew 26% to $49.0 million
- Q4 2024 achieved positive adjusted EBITDA of $1.9 million
- Q4 2024 net loss improved 59% to $4.5 million
- Active U.S. physicians increased 23% to ~1,400
- Received Transitional Pass-Through payment status for Granite outpatient procedures
- Strong cash position of $150.0 million at year-end
Negative
- Full year 2024 adjusted EBITDA loss of $5.1 million
- Operating expenses increased 8% in Q4 2024
- Net loss of $30.9 million for full year 2024
- Expected gross margin decline to 77-78% in 2025 guidance
News Market Reaction 1 Alert
On the day this news was published, SIBN gained 5.55%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Achieves
SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period)
- Worldwide revenue of
$49.0 million , representing growth of ~26% - U.S. revenue of
$46.9 million , representing growth of ~28% - Gross margin of ~
79% - Net loss of
$4.5 million , representing an improvement of ~59% - Positive adjusted EBITDA of
$1.9 million , representing an improvement of ~139% - Ended the quarter with
$150.0 million in cash and equivalents, representing$0.8 million in net cash usage
Fiscal Year 2024 Highlights (all comparisons are to the prior year period)
- Worldwide revenue of
$167.2 million , representing growth of ~20% - U.S. revenue of
$158.4 million , representing growth of ~21% - Gross Margin of ~
79% - Net loss of
$30.9 million , representing an improvement of ~29% - Adjusted EBITDA loss of
$5.1 million , representing an improvement of ~71%
Recent Operational Highlights (any comparisons are to the prior year period)
- ~1,400 active U.S. physicians in the fourth quarter, representing an increase of
23% - Granted Transitional Pass-Through payment status effective January 1, 2025 for Granite outpatient procedures
- Received third Breakthrough Device Designation for a novel implant system
“2024 was a transformative year for SI-BONE. Years of innovation, strategic investments, and disciplined execution are delivering meaningful results, including record revenue and positive adjusted EBITDA in the fourth quarter. More than 2,000 U.S. physicians performed a SI-BONE procedure last year, improving the lives of nearly 18,000 patients,” said Laura Francis, Chief Executive Officer. “With a total addressable market of nearly 500,000 procedures, we are still in the early stages of unlocking SI-BONE's full potential for strong, sustainable, and highly profitable growth. In 2025, I am excited about the opportunities to further expand platform adoption, supported by reimbursement tailwinds, while advancing toward achieving positive annual AEBITDA and improving our margins.”
Fourth Quarter 2024 Financial Results
Worldwide revenue was
Gross profit was
Operating expenses increased ~
Operating loss improved by ~
Net loss improved by ~
Adjusted EBITDA improved by ~
Fiscal Year 2024 Financial Results
Worldwide revenue was
Gross profit was
Operating expenses increased ~
Operating loss improved by ~
Net loss improved by ~
Adjusted EBITDA improved by ~
Cash and marketable securities were
2025 Financial Guidance
SI-BONE expects 2025 worldwide revenue to be in the range of
Webcast Information
SI-BONE will host a conference call to discuss the fourth quarter 2024 financial results after market close on Monday, February 24, 2025 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
iFuse Bedrock Granite and SI-BONE are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Forward Looking Statements
The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, contained in this press release are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's devices. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filing on Form 10-K, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Use of Non-GAAP Financial Measures
SI-BONE uses adjusted EBITDA, a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization, and stock-based compensation. SI-BONE believes the presentation of adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.
Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease SI-BONE's reported results of operations, management strongly encourages investors to review, when they become available, the company's consolidated financial statements and publicly filed reports in their entirety. The company's definition of adjusted EBITDA may differ from similarly titled measures used by others.
Investor Contact
Saqib Iqbal
Sr. Director, FP&A and Investor Relations
investors@SI-BONE.com
| SI-BONE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) (Unaudited) | |||||||||||||||
| Three Months Ended December 31, 2024 | Twelve Months Ended December 31, 2024 | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 49,002 | $ | 38,859 | $ | 167,178 | $ | 138,886 | |||||||
| Cost of goods sold | 10,225 | 10,183 | 35,057 | 29,466 | |||||||||||
| Gross profit | 38,777 | 28,676 | 132,121 | 109,420 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 31,249 | 28,937 | 117,054 | 110,254 | |||||||||||
| Research and development | 3,870 | 4,162 | 16,560 | 15,028 | |||||||||||
| General and administrative | 9,152 | 8,083 | 33,755 | 31,069 | |||||||||||
| Total operating expenses | 44,271 | 41,182 | 167,369 | 156,351 | |||||||||||
| Loss from operations | (5,494 | ) | (12,506 | ) | (35,248 | ) | (46,931 | ) | |||||||
| Interest and other income (expense), net: | |||||||||||||||
| Interest income | 1,784 | 2,228 | 7,848 | 6,916 | |||||||||||
| Interest expense | (795 | ) | (890 | ) | (3,440 | ) | (3,462 | ) | |||||||
| Other income (expense), net | 10 | 185 | (73 | ) | 141 | ||||||||||
| Net loss | $ | (4,496 | ) | $ | (10,983 | ) | $ | (30,913 | ) | $ | (43,336 | ) | |||
| Net loss per share, basic and diluted | $ | (0.11 | ) | $ | (0.27 | ) | $ | (0.75 | ) | $ | (1.13 | ) | |||
| Weighted-average number of common shares used to compute basic and diluted net loss per share | 41,994,284 | 40,579,409 | 41,466,564 | 38,427,419 | |||||||||||
| SI-BONE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) | |||||||
| December 31, 2024 | December 31, 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 34,948 | $ | 33,271 | |||
| Short-term investments | 115,094 | 132,748 | |||||
| Accounts receivable, net | 27,459 | 21,953 | |||||
| Inventory | 27,074 | 20,249 | |||||
| Prepaid expenses and other current assets | 3,204 | 3,173 | |||||
| Total current assets | 207,779 | 211,394 | |||||
| Property and equipment, net | 20,374 | 16,000 | |||||
| Operating lease right-of-use assets | 1,984 | 2,706 | |||||
| Other non-current assets | 300 | 325 | |||||
| TOTAL ASSETS | $ | 230,437 | $ | 230,425 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,488 | $ | 4,588 | |||
| Accrued liabilities and other | 19,492 | 17,452 | |||||
| Operating lease liabilities, current portion | 1,152 | 1,416 | |||||
| Total current liabilities | 27,132 | 23,456 | |||||
| Long-term borrowings | 35,452 | 36,065 | |||||
| Operating lease liabilities, net of current portion | 879 | 1,511 | |||||
| Other long-term liabilities | 10 | 18 | |||||
| TOTAL LIABILITIES | 63,473 | 61,050 | |||||
| Stockholders' Equity: | |||||||
| Common stock and additional paid-in capital | 598,074 | 569,481 | |||||
| Accumulated other comprehensive income | 244 | 335 | |||||
| Accumulated deficit | (431,354 | ) | (400,441 | ) | |||
| TOTAL STOCKHOLDERS’ EQUITY | 166,964 | 169,375 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 230,437 | $ | 230,425 | |||
| SI-BONE, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (In thousands) (unaudited) | |||||||||||||||
| Three Months Ended December 31, 2024 | Twelve Months Ended December 31, 2024 | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net loss | $ | (4,496 | ) | $ | (10,983 | ) | $ | (30,913 | ) | $ | (43,336 | ) | |||
| Interest income | (1,784 | ) | (2,228 | ) | (7,848 | ) | (6,916 | ) | |||||||
| Interest expense | 795 | 890 | 3,440 | 3,462 | |||||||||||
| Depreciation and amortization | 1,213 | 1,573 | 4,379 | 5,428 | |||||||||||
| Stock-based compensation | 6,135 | 5,937 | 25,868 | 24,057 | |||||||||||
| Adjusted EBITDA | $ | 1,864 | $ | (4,811 | ) | $ | (5,074 | ) | $ | (17,305 | ) | ||||
FAQ
What was SI-BONE's (SIBN) revenue growth in Q4 2024?
When will SI-BONE (SIBN) achieve positive adjusted EBITDA in 2025?
What is SI-BONE's (SIBN) revenue guidance for 2025?
How much did SI-BONE's (SIBN) net loss improve in 2024?
What was SI-BONE's (SIBN) cash position at the end of 2024?
